ANAPTYSBIO, INC. Number of Reportable Segments
ANAPTYSBIO, INC. (ANAB) reported Number of Reportable Segments of 1 Segment for the 6-month period ending 2026-06-30, per its 10-KT filed 2026-09-21.
Financial Statements › Notes › Segment Reporting
us-gaap:NumberOfReportableSegments · last filed 2026-09-21
- ANAPTYSBIO, INC. number of reportable segments for the quarter ending 2025-03-31 was 1.00 segment, a 0.00% change year-over-year.
- ANAPTYSBIO, INC. number of reportable segments for the quarter ending 2024-03-31 was 1.00 segment, a 0.00% change year-over-year.
- ANAPTYSBIO, INC. number of reportable segments for the quarter ending 2023-03-31 was 1.00 segment, a 0.00% change year-over-year.
- ANAPTYSBIO, INC. number of reportable segments for the quarter ending 2022-03-31 was 1.00 segment, a 0.00% change year-over-year.
- ANAPTYSBIO, INC. number of reportable segments for fiscal 2024 was 1.00 segment, a 0.00% change from fiscal 2023.
- ANAPTYSBIO, INC. number of reportable segments for fiscal 2023 was 1.00 segment, a 0.00% change from fiscal 2022.
- ANAPTYSBIO, INC. number of reportable segments for fiscal 2022 was 1.00 segment, a 0.00% change from fiscal 2021.
- ANAPTYSBIO, INC. number of reportable segments for fiscal 2021 was 1.00 segment, a 0.00% change from fiscal 2020.
segment
| Period end | Number of Reportable Segments 3 month | Number of Reportable Segments 6 month | Number of Reportable Segments 9 month | Number of Reportable Segments 12 month |
|---|---|---|---|---|
| 2025-09-30 | 1.00 segment 10-Q · filed 2025-11-04 | |||
| 2025-06-30 | 1.00 segment 10-Q · filed 2025-08-06 | |||
| 2025-03-31 | 1.00 segment 10-Q · filed 2025-05-05 | |||
| 2024-12-31 | 1.00 segment 10-K · filed 2025-02-27 | |||
| 2024-09-30 | 1.00 segment 10-Q · filed 2024-11-05 | |||
| 2024-06-30 | 1.00 segment 10-Q · filed 2024-08-05 | |||
| 2024-03-31 | 1.00 segment 10-Q · filed 2024-05-09 | |||
| 2023-12-31 | 1.00 segment 10-K · filed 2024-03-11 | |||
| 2023-09-30 | 1.00 segment 10-Q · filed 2023-11-02 | |||
| 2023-06-30 | 1.00 segment 10-Q · filed 2023-08-07 | |||
| 2023-03-31 | 1.00 segment 10-Q · filed 2023-05-11 | |||
| 2022-12-31 | 1.00 segment 10-K · filed 2023-03-01 | |||
| 2022-09-30 | 1.00 segment 10-Q · filed 2022-11-08 | |||
| 2022-06-30 | 1.00 segment 10-Q · filed 2022-08-08 | |||
| 2022-03-31 | 1.00 segment 10-Q · filed 2022-05-04 | |||
| 2021-12-31 | 1.00 segment 10-K · filed 2022-03-07 | |||
| 2021-09-30 | 1.00 segment 10-Q · filed 2021-11-04 | |||
| 2021-06-30 | 1.00 segment 10-Q · filed 2021-08-09 | |||
| 2021-03-31 | 1.00 segment 10-Q · filed 2021-05-04 | |||
| 2020-12-31 | 1.00 segment 10-K · filed 2021-02-25 | |||
| 2020-09-30 | 1.00 segment 10-Q · filed 2020-11-04 | |||
| 2020-06-30 | 1.00 segment 10-Q · filed 2020-08-10 | |||
| 2020-03-31 | 1.00 segment 10-Q · filed 2020-05-06 | |||
| 2019-12-31 | 1.00 segment 10-K · filed 2020-03-02 | |||
| 2019-09-30 | 1.00 segment 10-Q · filed 2019-11-08 | |||
| 2019-06-30 | 1.00 segment 10-Q · filed 2019-08-08 | |||
| 2019-03-31 | 1.00 segment 10-Q · filed 2019-05-07 | |||
| 2018-12-31 | 1.00 segment 10-K · filed 2019-02-28 | |||
| 2018-09-30 | 1.00 segment 10-Q · filed 2018-11-08 | |||
| 2018-06-30 | 1.00 segment 10-Q · filed 2018-08-07 | |||
| 2018-03-31 | 1.00 segment 10-Q · filed 2018-05-08 | |||
| 2017-12-31 | 1.00 segment 10-K · filed 2018-03-05 | |||
| 2017-09-30 | 1.00 segment 10-Q · filed 2017-11-07 | |||
| 2017-06-30 | 1.00 segment 10-Q · filed 2017-08-10 | |||
| 2017-03-31 | 1.00 segment 10-Q · filed 2017-05-12 |
Segment
| Period end | Number of Reportable Segments 3 month | Number of Reportable Segments 6 month | Number of Reportable Segments 12 month |
|---|---|---|---|
| 2026-06-30 | 1.00 Segment 10-KT · filed 2026-09-21 | ||
| 2026-03-31 | 2.00 Segment 10-Q · filed 2026-05-12 | ||
| 2025-12-31 | 2.00 Segment 10-K · filed 2026-03-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |